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Abstract
Background: There are numerous, disparate guidelines for influenza vaccination in egg-allergic patients. We aimed
to describe the outcome of selectively applied guidelines, based on risk-stratification, to our high risk, egg-allergic,
tertiary-care pediatric population.
Methods: Egg allergy was confirmed with skin testing. The vaccine administered was an adjuvunated 2009 H1N1
influenza A vaccine with < 0.165 mcg/ml ovalbumin. Patients with mild egg allergy were to receive the vaccination
in 1 dose, those with severe egg allergy were to receive 2 split doses, and patients with exquisite egg allergy or
significant co-morbidities were to be skin tested with the vaccine (prick full strength, intradermal 1:100 of final
concentration without adjuvant) and had 5 step desensitization if the testing was positive, or 1-2 step
administration if negative. Patients were observed for 60 minutes after the final dose and anaphylaxis treatment
was available. We report the frequency of allergic reactions.
Results: Ninety-nine patients were referred and 79 had positive egg testing. Asthma was present in 67% and 30%
had prior anaphylaxis to egg. We vaccinated 77 of 79 patients: 71 without performing vaccine skin testing. Two
refused vaccination. No patient had a systemic reaction or required treatment. Two patients experienced positive
testing to the adjuvanated intradermal vaccine, but were negative without adjuvant.
Conclusions: Our results suggest that most egg-allergic tertiary care pediatric patients can be vaccinated with a
low ovalbumin content influenza vaccine without prior vaccine testing. Vaccine skin testing, if used at all, can be
reserved for special circumstances. The squalene adjuvant may cause an irritant reaction with intradermal testing.
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Background
Influenza vaccination has traditionally been contraindi-
cated in individuals with egg allergy [1,2] due to the
possibility of an allergic reaction to residual egg pro-
teins. Approaches have been recommended to vaccinate
egg-allergic individuals. One approach recommends skin
testing prior to vaccination [3] and use of a graded chal-
lenge [4]. However, there has been evidence demonstrat-
ing that the influenza skin testing may not be predictive
of reactions [5-7] and intradermal testing has been
shown to have an irritant response [8]. There is no such
data on intradermal skin testing performance with an
adjuvanated influenza vaccine.
Another approach is to give the vaccine in two doses
as described in 1997 by James et al. [6]. This evidence
was used by the 2009 vaccine allergy practice para-
meters [9] to recommend that if the ovalbumin content
is known to be less than 1.2 mcg/ml then the vaccine
can be given as 10% followed in 30 minutes by 90%, or
as a single dose, without prior testing. In 2009 the Cana-
dian Society of Allergy and Clinical Immunology
(CSACI) [10] and a review in the British Medical Jour-
nal [11] included a risk-stratification suggestion such
that low-risk individuals could be vaccinated in one
dose while higher risk would receive split-dosing. How-
ever, this approach was not endorsed by some other
guidelines, such as the Red Book [1], and the European
Academy of Allergy and Clinical Immunology [12].
Adjuvunated influenza vaccines have been used in
Europe since 1997 [13]. In the 2009 H1N1 influenza A
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enza vaccine for the first time and it was known that
this vaccine had < 0.165 mcg/ml ovalbumin. At the
Hospital for Sick Children in Toronto, Canada, we
hypothesized that the majority of egg-allergic individuals
could be vaccinated with a one or two dose regimen
without vaccine prior skin testing, as per the CSACI
guidelines, and that vaccine skin testing could be
reserved for exquisitely high-risk patients. Importantly,
we hypothesized that testing the vaccine itself, without
the adjuvant, would reduce the frequency of irritant
responses and avoid any potential immunological con-
cerns about intradermal injection of squalene [14]. We
demonstrate here the safety and efficacy of our approach
in a large group of tertiary care pediatric patients and
add to the literature more experience with anaphylactic
patients and with the skin testing of squalene-adjuvu-
nated vaccines.
Methods
The study was conducted at The Hospital for Sick Chil-
dren, Toronto. The protocol was developed in Novem-
ber 2009. Our inclusion criteria were all patients seen in
the Egg Allergy-pH1N1 vaccination clinics. The diagno-
sis of egg allergy was assessed with commercially avail-
able egg extract SPT within the last 6 months. This
cohort included children that had never eaten eggs.
Patients were excluded if their SPT was negative to
eggs, or clearly tolerating eating eggs other than in
baked products. Specific IgE levels to egg were not
assessed.
Egg-allergic patients were assessed at the time of clinic
for the severity of their egg reaction, prior influenza
reactions and co-morbid conditions. Figure 1 presents
the algorithm provided to physicians. Patients were to
be classified as “mild egg allergy” if they had never
experienced any generalized reaction of urticaria,
angioedema, or respiratory reactions to egg and were to
be vaccinated in one dose and be monitored for 60 min-
utes. This “mild egg allergy” category would include, for
example, gastrointestinal reactions alone and patients
who had never ingested egg but had positive skin prick
tests, Patients were to be classified as “severe egg
allergy” if they had any generalized reaction to egg and
were to be administered the pH1N1 vaccine in split
doses of 10% and then the remainder if there was no
reaction. This category of patients would include
patients who had urticaria/angioedema to egg, or
respiratory reactions to egg, as well as anaphylaxis. The
classification of “exquisite egg allergy and/or significant
co-morbidity” was to be used if it was determined by
the physician that their egg allergy history or their co-
morbidities were so severe that skin testing was indi-
cated prior to vaccination. Examples of the type of
patient that may be classified in this category may
include a patient who experienced anaphylaxis requiring
an intensive care admission, or one who experienced
anaphylaxis from only touching an egg shell, or a non-
verbal patient who would not be able to alert the physi-
cian to early signs of an allergic reaction. These patients
were to have SPT with full strength vaccine. If negative
they were to be intradermally tested with 1:200 of the
antigen solution of the vaccine without the adjuvant.
This dilution is 1:100 of the final concentration of the
vaccine because in vaccine preparation equal parts of
antigen vial and adjuvant vial are mixed. If skin tests
were positive the vaccine was offered in a 5 step graded
challenge. If testing was negative the vaccine was offered
in a single or two dose regimen at the physician’s
discretion.
If the initial vaccine was well tolerated, the follow-up
booster vaccine was recommended to come from the
same lot as the initial vaccine and could be administered
outside this institution. Written consent to vaccination
was taken at the time of clinic visit. Patients could
refuse vaccination. Anaphylaxis was assessed according
to criteria defined by the National Institute of Health in
2006 [15]. The actual decision as to how to manage the
patient was guided by protocol but was individualized.
The adjuvunated influenza vaccine used was Glaxo
Smith Kline’sA r e p a n r i x
®. It contained less than 0.165
mcg/ml ovalbumin once prepared and typically con-
tained much less (written personal communication,
Glaxo Smith Kline). It is an inactivated, split influenza
virus vaccine which used the squalene based adjuvant
ASO3. The vaccine was administered intramuscularly
according to age specific doses. Commercial egg extract,
histamine and saline were from Omega Laboratories
LTD. A positive test was 3 mm larger than the saline
control. SPT was performed with stainless steel lancet-
ters (Medipoint) and intradermal testing was performed
with 27 gauge needles.
The main outcome measures were adverse events:
minor allergic reaction (hives, angioedema), or serious
adverse event (anaphylactic reactions to influenza vac-
cine). If allergic reactions occurred then a description of
the possible predisposing factors was to be attempted.
Statistical analysis was descriptive. The occurrence of
allergic reactions to the vaccine was to be reported as a
simple frequency. This study received approval of the
Hospital for Sick Children Research Ethics Board.
Results
Patient characteristics
Ninety-nine patients thought to be egg-allergic were
referred for administration of the pH1N1 vaccination.
Twenty patients were found to be routinely eating egg
or had negative skin prick testing to egg and were
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teristics are listed in Table 1. A clear history of anaphy-
laxis to egg was found in 30%, and almost 9% had used
epinephrine. One fifth of our patients had reacted to
egg within the last 2 years. Most (60%) were avoiding
egg entirely and not eating it in baked goods. Over 67%
of our patients had asthma and almost 76% had other
food allergies. Only 19% of our patients were known to
have received the influenza vaccine in the past. All had
tolerated the vaccine. Four patients had negative influ-
enza vaccine testing in the past. Almost 4% of our
patients had a history of positive influenza testing in
prior years and 1% had been desensitized in prior years.
On referral, almost 4% of patients had positive testing
with the pH1N1 adjuvunated vaccine. Fifteen percent of
our patients had other serious medical conditions such
as spastic quadriplegia, liver transplants, acute lympho-
blastic leukemia, and chromosomal abnormalities.
Management of patients
Figure 2 presents the management of our patients. Of
the 79 egg-allergic patients, 71 were not tested to the
vaccine and 8 were tested to the vaccine. Of these 71
patients not tested to vaccine, 16 patients were given
the vaccine as a single dose, 53 were given the vaccine
as a two dose regimen (including 2 with a history of
positive influenza vaccine skin test in a prior year), and
two patients refused the vaccine (1 decided the wait was
Figure 1 Protocol for the Management of Egg-Allergic Patients Referred for Adjuvuanted Pandemic H1N1 Influenza A Vaccination.
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vaccinated in a single dose had the following histories of
reaction to egg ingestion: 7 had never eaten egg, 2 had
urticaria and/or angioedema, 2 had anaphylaxis (skin
and gastrointestinal symptoms), 2 had a perioral rash, 1
had pruritis alone, 1 had urticaria to an unknown food,
1 had gastrointestinal symptoms only, and for one
patient there was no data. The 53 patients vaccinated in
two doses had the following histories of reaction to egg:
18 had urticaria and/or angioedema, 17 had anaphylaxis
to egg, 10 had never eaten egg, 1 had anaphylaxis to an
unknown food, 1 had urticaria and throat tightness, 1
had a perioral rash, 2 had gastrointestinal symptoms
only, 1 had a reaction to egg not remembered well
enough to describe and for 2 patients there was no data.
There were 13 patients with “mild egg allergy” based on
their histories that were given the vaccine in the more
cautious two graded dose regimen whereas the algo-
rithm suggested a single dose. Three patients were given
t h ev a c c i n ei nas i n g l ed o s ew h e nt w ow e r es u g g e s t e d
by our algorithm based on their egg history. No patient
had any reaction to the vaccine.
Of the 8 patients that were tested to vaccine, 3 were
tested because of positive tests to the pH1N1 adjuva-
nated vaccine in the community prior to the visit to our
clinic by our co-author Dr. Hummel; one had a positive
prick test and two had positive testing to the 1:100
intradermal pH1N1 adjuvanated vaccine. The remainder
were tested due to histories of severe anaphylaxis.
Importantly, the two patients that had positive intrader-
mal tests to the adjuvanated pH1N1 vaccine at 1:100
tested negative without adjuvant. The vaccine was given
in two doses to these patients and in one to the other
negative testing patients. Two patients had positive
prick tests to the vaccine and the administration was
performed in a 5 dose regimen. One of these patients
had hives at the site of injection on the first diluted
dose but no subsequent local or systemic reaction to the
subsequent doses. In one patient prick testing was per-
f o r m e dd u et oaf i s ha l l e r g y( t h er a t i o n a l ef o rt h i st e s t -
ing was squalene adjuvant is fish oil based and the cross
reactivity was unknown) and a history of recent anaphy-
l a x i s ;t h et e s t i n gw a sn e g a t i v ea n dat w od o s er e g i m e n
was used. We had no positive intradermal tests to the
Table 1 Patient Characteristics of The Egg-Sensitized Patients Offered Influenza Vaccine
Variable No. % Variable No. %
Egg Reactions Other Atopic Disease
Anaphylaxis to egg 24 30.4 Asthma 53 67.1
Urticaria and throat tightness 1 1.3 Other Food Allergies 60 75.9
Limited to gastrointestinal system 5 6.3 Other Significant Co-Morbidities 79 100.0
Urticaria and/or angioedema 21 26.6 Neurological Conditions
Pruritis 1 1.3 Significant Hematological Conditions 3 3.8
Mouth sensation 1 1.3 Liver transplants 2 2.5
Perioral rash 3 3.8 T1 DM 3 3.8
Urticaria/angioedema possibly to egg 1 1.3 Significant Failure to Thrive 2 2.5
Unsure of reaction 2 2.5 Trisomy 1 1.3
Positive skin prick test only 17 21.5 Age at Consultation for H1N1 Vaccine
Data not available 3 3.8 0-2 years old
TOTAL 79 100.0 3-5 years old 12 15.2
Anaphylaxis to unknown food that
could be egg
2 2.5 6-9 years old 24 30.4
Recent reaction to egg ( < 2 years) 16 20.3 10-13 years old 28 35.4
Eating baked egg 14 years and older 10 12.7
Yes 15 19.0 Influenza Testing History 79 100.0
No 48 60.8 + Test to Influenza Vaccine < 2009 3 3.8
Data not available 16 20.3 + Test to 2009 H1N1 in Community 3 3.8
Epinephrine Use Influenza Vaccine History
For egg reaction 7 8.9 Received Influenza Vaccine
Previously
15 19.0
Unsure if part of treatment for egg
reaction
1 1.3 Received Influenza Vaccine by
Desensitization
1 1.3
For reaction to unknown food (possibly
egg)
3 3.8 Never Had Influenza Vacine 36 45.6
Unknown 27 34.2
TOTAL 79 100.0
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vaccine tolerated it with no systemic adverse event. No
patient had any significant reaction to the vaccine.
Discussion
The egg-allergic patient population we evaluated for
vaccination was a tertiary pediatric practice with a high
level of anaphylaxis, significant co-morbid conditions,
and some with positive flu vaccine tests. Despite this we
successfully vaccinated 77 of 79 patients and only skin
tested 8/79 patients by using a risk-stratified approach.
T h eo n l y2w ed i dn o tv a c c i n a t ew e r ed u et op a t i e n t
refusal. No patients had a systemic reaction to vaccina-
tion.Some patients received a different administration of
vaccine than dictated by their egg allergy alone. There
were 13 patients with “mild egg allergy” that were given
the vaccine in two graded doses whereas the algorithm
suggested a single dose by their egg history alone. Some
of these patients had complex medical conditions. For
example, one had sickle cell anemia, one had a liver
transplant, and one had cerebral palsy and was in a
wheelchair. While these conditions are not related to
atopy, they may make the recognition and management
of a serious allergic reaction more difficult or lessen the
parents or physician’s comfort level with risk. Adminis-
tration of vaccine without prior testing was a change
from previous years so the use of the perceived more
cautious approach (split dosing rather than single
Figure 2 Flow Diagram Showing Management and Outcome of Patients.
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tested to the vaccine were given the vaccine in a single
dose when two were suggested by our algorithm. Two
of these patients had hives and angioedema to egg and
one had a combined skin and gastrointestinal reaction.
These reactions were determined by the treating physi-
cian to be mild and were thus triaged to a single dose.
None of these patients had a systemic reaction to the
vaccine. The algorithm was only a suggestion and the
flexibility for the physician or family to choose a more
cautious regimen likely helped compliance.
All of our vaccinated patients tolerated the vaccine so
it is certainly possible that they would have all tolerated
the vaccine in a one dose method, although our patient
who received the vaccine in 5 steps had localized hives
at the injection site to the first diluted dose; we do not
know what the reaction would have been if this patient
had received only split dosing or full dosing. Likely this
was just a reflection of her cutaneous sensitivity to the
vaccine as evidenced by her positive skin tests. A multi-
center trial is ongoing to establish the safety of single
dosing of influenza vaccine versus split dosing in
patients with severe reactions [16] so there may soon be
more evidence that even patients with severe reactions
can tolerate single dosing without prior vaccine testing.
In addition, there have been a number of papers pub-
lished on different experiences with the 2009 vaccina-
tion campaign in egg-allergic individuals. The largest
study to date of influenza vaccination in egg-allergic
patients [17] is a prospective study in which patients
were risk-stratified by history to receive the vaccine
without prior vaccine testing in one dose if low-risk or
in a split-dose regimen if they were high-risk. In this
study none of 830 vaccinations resulted in anaphylaxis,
but one patient needed an antihistamine in the first
hour, and one needed salbutamol. Further vaccination
of more than 3600 patients resulted in 69 patients devel-
oping a possible allergic reaction and two uses of epi-
nephrine. This study supports that egg-allergic patients
can receive the egg containing vaccine without prior
vaccine testing, but some caution is required.
As of October 2010, the American Academy of
Allergy, Asthma and Immunology (AAAAI) no longer
recommends routine influenza vaccine skin testing for
egg-allergic individuals and has updated guidelines for
November 2011 [18] . This organization now recom-
mends a single step vaccine strategy for most patients.
A one step or two step approach with no routine skin
testing of vaccine is recommended in a recent editorial
[19] and in a new focused practice parameter update for
the Joint Task Force on Practice Parameters [20]. How-
ever, for example, a Cincinnati group [21] and the Brit-
ish Society of Allergy and Clinical Immunology endorse
a skin testing based approach [22]. The Red Book [1]
has issued an update to their guidelines that some egg-
allergic individuals may be vaccinated without prior skin
testing with a low albumin vaccine in one or two steps
in an appropriate setting, but these recommendations
are said to be not applicable to the egg-allergic person
with a history of anaphylaxis or severe allergy. Recently,
the Advisory Committee on Immunization Practices
from the Centers for Disease Control and Prevention
issued their recommendations [23] that someone who
experiences only hives to eating egg can receive the
killed influenza vaccine in one dose with at least a 30
minute wait. Patients with more significant symptoms
should be evaluated by an allergist. In October 2011 the
Canadian Pediatric Society issued guidelines [24] in
which a risk stratification system is recommended to
decide between one or two step vaccination with no
prior influenza vaccine testing. In these guidelines, peo-
ple who experienced generalized reactions, including
generalized urticaria, to egg would be deemed “higher
risk” and vaccinated with a two step regimen. The pre-
sence of multiple differing guidelines suggests that more
information is still needed.
There are some limitations to our study. Egg allergy
was not confirmed by oral challenge, therefore there
w e r el i k e l ys o m es k i nt e s tp o s i t i v eo n l yc h i l d r e nn o t
actually allergic to eggs. However, these children only
totaled 17 patients. Another limitation is that only 16
patients (20.3%) had a history of egg reaction within the
past 2 years. Therefore, some patients, including some
of these patients that we described as having a recent
reaction, may have outgrown clinical egg allergy. Fol-
low-up for delayed reactions was by voluntary reporting
although our observation period was long enough to
assess for most anaphylactic reactions. This vaccine had
very low egg content and therefore these findings may
not apply to higher egg content vaccines. Our overall
patient numbers were small; however our number of
patients with a history of anaphylaxis, 24, contributes to
the literature because the largest number of patients
with a severe reaction receiving an egg containing influ-
enza vaccine reported in a study so far has been the 72/
830 reported by Gagnon et al. [17].
Risk stratifying patients by their prior reaction to eat-
ing egg suggests that the prior history is indicative of
their risk of reaction. This presumption may not be true
[25]. As another level of caution, in our protocol we
suggested that the follow up vaccine (if required) should
be from the same lot. This may also be unnecessary
[25].
We had two patients referred with positive intrader-
mal testing to the vaccine diluted to 1:100 of the final
concentration who did not test positive when tested
without adjuvant. Given this potentially irritant
response, as well as issues regarding the potential
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recommend that if squalene containing vaccines need to
be intradermally tested they are tested without the adju-
vant. Although our numbers are small, to our knowl-
edge there is no other reported experience of
intradermal testing of a vaccine with squalene.
Conclusion
Our study showed that most egg-allergic, tertiary-care
pediatric patients can be safely vaccinated with a low-
ovalbumin content influenza vaccine without prior vac-
cine testing and that vaccine testing and desensitization
in egg-allergic patients, if used at all, can be reserved for
special circumstances. We only vaccine tested patients
deemed to have exquisite egg allergy and/or significant
co-morbidity (8 of our 79 patients) and only 2 of our
patients had a positive prick test and they still tolerated
the vaccine in a graded challenge. We found that the
adjuvant likely has an irritant response on intradermal
testing. This study adds another 24 patients to the cur-
r e n tb o d yo fe v i d e n c et h a te v e np a t i e n t sw i t hap r i o r
history of anaphylaxis to egg can receive an egg-contain-
ing influenza vaccine. Based on available evidence, many
guidelines now conclude that egg-allergic individuals do
not benefit from vaccine skin testing prior to low-oval-
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